ArticleBMJ open2019

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration.

Barbara Willekens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.